ESWT vs Conventional Physical Therapy in Greater Trochanteric Pain Syndrome

Greater Trochanteric Pain Syndrome (GTPS) is a frequent cause of lateral hip pain and is now understood to be primarily associated with gluteus medius and minimus tendinopathy rather than inflammation of the trochanteric bursa. Although several conservative treatments are available, including nonsteroidal anti-inflammatory drugs and physical therapy modalities, there is no consensus on the most effective treatment strategy. Extracorporeal Shockwave Therapy (ESWT) has emerged as a potential non-invasive treatment option that may promote tissue regeneration, reduce pain, and improve tendon healing.

This prospective randomized controlled trial will include 60 patients aged 18-65 years with MRI-confirmed GTPS. Participants will be randomly assigned (1:1) to either the ESWT group or the conventional physical therapy group. The ESWT group will receive five sessions over 3 weeks (15 Hz, 3 bar, 2000 pulses). The physical therapy group will receive 10 sessions of TENS (20 minutes), hot pack (20 minutes), and continuous ultrasound (1.5 W/cm², 5 minutes). Both groups will be given a standardized exercise program.

Outcome measures include the Visual Analog Scale (VAS) for pain (night, rest, activity), Harris Hip Score, Lower Extremity Functional Scale (LEFS), and the Global Rating of Change Scale. Assessments will be performed at baseline, week 3, and week 12. The primary objective is to compare the effect of ESWT versus conventional physical therapy on pain reduction. Secondary objectives include evaluating functional improvements and global patient satisfaction.

Inclusion criteria

• Age between 18 and 65 years
• Lateral hip pain for at least 3 months
• Ability to understand study procedures and provide informed consent

Exclusion criteria

• Hip deformities
• Gluteus medius, gluteus minimus, or piriformis tendon tears
• Lumbar radiculopathy or history of lumbar spine surgery
• Recent trauma or active infection in the hip region
• Corticosteroid injection to the hip within the last 6 months
• Neurological, psychiatric, or rheumatologic diseases
• Active malignancy or systemic inflammatory disease
• Cognitive impairment preventing cooperation